Robert Barrie is a journalist specializing in the medical and pharmaceutical industries. He writes for publications such as Medical Device Network, Pharmaceutical-Technology, and Clinical Trials Arena, covering topics ranging from new medical devices and therapies to clinical trial advancements. His work has also been featured in The Redstone Rocket.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Robert Barrie appears to focus extensively on the healthcare and pharmaceutical industry, with a particular emphasis on company announcements and press releases. To effectively reach out to Robert, consider providing insights or exclusive information related to major developments within the pharmaceutical industry such as clinical trial results, FDA decisions, medical device advancements or biotech startup breakthroughs.
As Robert's coverage heavily features private sector announcements and press releases, ensure that any pitch includes newsworthy updates backed by credible sources. Additionally, offering exclusive interviews with key figures in the healthcare and pharmaceutical sector could increase the chances of successful outreach.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Robert Barrie
The biopharma industry should be proactive in its approach to changing requirements for diversity in clinical trial populations.
By: Robert Barrie
Cost of litigation resolution is lower than expected as shares in the company bounce back.
By: Robert Barrie
Bitterroot Bio has dosed the first participants in a Phase I trial investigating its candidate for the treatment of atherosclerotic cardiovascular disease.
By: Robert Barrie
Liberate has started patient enrolment in the PREVENT trial with funding from the US Department of Defense.
By: Robert Barrie
SecondWave is now eyeing larger controlled trials with its non-invasive ultrasound therapy.
By: Robert Barrie
The operational changes are expected to save the biotech and manufacturing organisation $80m annually.
More diverse study designs and better recruitment numbers mean the West Coast is a leading region for oncology trials worldwide.
By: Robert Barrie
Experts say recognising initiatives that worked well and those that did not are both important in tackling diversity going forward.
By: Robert Barrie
The number of pharma companies utilising AI across a medicine’s lifecycle is growing rapidly
By: Robert Barrie
Already CE marked, Reflow has completed enrolment in a US trial for its retrievable stent therapy device.
(833) 317-6278 
